Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in hiv/hcv-coinfected patients

HIV Clinical Trials, 04/23/2012

Regimens including EFV, NVP, or PI/r are generally safe in treatment–naïve HIV/HCV–coinfected patients. Grade 3–4 TE are less commonly seen with EFV than with PI/r. Discontinuations due to hepatotoxicity were less frequent for patients receiving EFV than for those treated with NVP.

Print Article Summary Cat 2 CME Report